Traders Buy Large Volume of Roivant Sciences Put Options (NASDAQ:ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV) was the recipient of some unusual options trading on Wednesday. Stock investors purchased 2,086 put options on the stock. This represents an increase of 83% compared to the typical daily volume of 1,137 put options.

Insider Transactions at Roivant Sciences

In related news, insider Frank Torti sold 587,390 shares of Roivant Sciences stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $27.51, for a total value of $16,159,098.90. Following the completion of the sale, the insider owned 13,736,547 shares of the company’s stock, valued at approximately $377,892,407.97. This trade represents a 4.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Jennifer Humes sold 13,538 shares of the business’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the sale, the chief accounting officer owned 84,191 shares in the company, valued at $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 3,745,173 shares of company stock valued at $103,639,917. 10.80% of the stock is currently owned by insiders.

Institutional Trading of Roivant Sciences

Several institutional investors and hedge funds have recently made changes to their positions in ROIV. Fifth Third Bancorp grew its position in Roivant Sciences by 8.7% in the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after acquiring an additional 376 shares in the last quarter. Bessemer Group Inc. lifted its stake in Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after purchasing an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its holdings in shares of Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock worth $282,000 after purchasing an additional 445 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after purchasing an additional 500 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Roivant Sciences by 1.3% during the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock valued at $868,000 after buying an additional 516 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV traded up $3.79 on Wednesday, hitting $32.00. The company’s stock had a trading volume of 4,650,212 shares, compared to its average volume of 5,942,261. The company has a market capitalization of $22.90 billion, a PE ratio of -27.29 and a beta of 1.14. The company has a 50-day simple moving average of $28.38 and a 200 day simple moving average of $24.85. Roivant Sciences has a 1 year low of $10.59 and a 1 year high of $32.53.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Thursday, May 21st. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.54. Roivant Sciences had a negative net margin of 6,079.94% and a negative return on equity of 19.04%. During the same period in the previous year, the business earned ($0.29) EPS. On average, equities research analysts expect that Roivant Sciences will post -1.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Roivant Sciences in a research report on Friday, May 8th. Piper Sandler boosted their target price on shares of Roivant Sciences from $22.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 16th. Citigroup raised their price target on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, Sanford C. Bernstein started coverage on Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 price objective on the stock. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $30.55.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.